TRAIL and Noxa are selectively upregulated in prostate cancer cells downstream of the RIG-I/MAVS signaling pathway by nonreplicating Sendai virus particles

Clinical Cancer Research

Volumn 18, Issue 22, 2012, Pages 6271-6283

  Matsushima Miyagi, Taeko ^a   Hatano, Koji ^a,b   Nomura, Motonari ^a,b   Li Wen, Liu ^a   Nishikawa, Tomoyuki ^a   Saga, Kotaro ^a   Shimbo, Takashi ^a,c   Kaneda, Yasufumi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; LIPOSOME; MITOCHONDRIAL ANTIVIRAL SIGNALING PROTEIN; ONCOLYTIC VIRUS; PROTEIN NOXA; RETINOIC ACID INDUCIBLE PROTEIN I; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROSTATE EPITHELIUM; SENDAI VIRUS; SIGNAL TRANSDUCTION; ULTRAVIOLET RADIATION; UPREGULATION; VIRUS GENOME; VIRUS PARTICLE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; DEAD-BOX RNA HELICASES; GENOME, VIRAL; HUMANS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; ONCOLYTIC VIRUSES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, VIRAL; SENDAI VIRUS; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR BURDEN; UP-REGULATION; VIRION; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84869233969     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1595     Document Type: Article

References (49)

1. Ciardiello F, Tortora G. Review. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958-70. (Pubitemid 32963812)
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics. CA Cancer J Clin 2008;58:71-96.
3. Gulley J, Figg WD, Dahut WL. Treatment options for androgen-independent prostate cancer. Clin Adv Hematol Oncol 2003;1:49-57.
4. Ziegler JL. Spontaneous remission in Burkitt's lymphoma. Natl Cancer Inst Monogr 1976;7:141-8.
5. Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther 2007;15:651-9. (Pubitemid 46431984)
6. Asada T. Treatment of human cancer with mumps virus. Cancer 1974;34:1907-28.
7. Newman W, Southam CM. Virus treatment in advanced cancer; a pathological study of fifty-seven cases. Cancer 1954;7:106-18.
8. Huebner RJ, Rowe WP, Schatten WE, Smith RR, Thomas LB. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 1956;9:1211-8.
9. Davis JJ, Fang B. Oncolytic virotherapy for cancer treatment: challenges and solutions. J Gene Med 2005;7:1380-9. (Pubitemid 41672396)
10. Russell SJ, Peng KW. Measles virus for cancer therapy. In:Grippin DE, Oldstone MBA, editors. Measles - pathogenesis and control. Berlin, Heidelberg: Springer-Verlag; 2009. p. 213-41.
11. Liu TC, Kirn D. Gene therapy progress and prospects cancer: oncolytic viruses. Gene Ther 2008;15:877-84. (Pubitemid 351791475)
12. Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 2009;9:64-71.
13. Thorne SH, Hwang TH, O'Gorman WE, Bartlett DL, Sei S, Kanji F, et al. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J Clin Invest 2007;117:3350-8. (Pubitemid 350096991)
14. Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 2011;477:99-102.
15. Freeman AI, Zakay-Ronez Z, Gomori JM, Linetsky E, Rasooly L, Greenbaum E, et al. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther 2005;13:221-8. (Pubitemid 41763501)
16. Msaouel P, Dispenzieli A, Galanis E. Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview. Curr Opin Mol Ther 2009;11:43-53.
17. Heinzerlin L, Künzi V, Oberholzer PA, Kündig T, Naim H, Dummer R. Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells. Blood 2005;106:2287-94. (Pubitemid 41510798)
18. Msaouel P, Iankov ID, Allen C, Morris JC, von Messling V, Cattaneo R, et al. Engineered measles virus as a novel oncolytic therapy against prostate cancer. Prostate 2008;69:82-91.
19. Patel B, Dey A, Ghorani E, Kumar S, Malam Y, Rai L, et al. Differential cytopathalogy and kinetics of measles oncolysis in two primary B-cell malignancies provides mechanistic insights. Mol Ther 2011;19:1034-40.
20. Guo ZS, Thorne SH, Bartlett DL. Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim Biophys Acta 2008;1785:217-31.
21. Kurooka M, Kaneda Y. Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells. Cancer Res 2007;67:227-36. (Pubitemid 46142779)
22. Fujihara A, Kurooka M, Miki T, Kaneda Y. Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation. Cancer Immunol Immunother 2008;57:73-84. (Pubitemid 350043650)
23. Kaneda Y. Update on non-viral delivery methods for cancer therapy: possibilities of DDS with anti-cancer activities beyond delivery as a new therapeutic tool. Expert Opin Drug Deliv 2010;9:1079-93.
24. Kawaguchi Y, Miyamoto Y, Inoue T, Kaneda Y. Efficient eradication of hormone-resistant human prostate cancers by inactivated Sendai virus particle. Int J Cancer 2009;124:2478-87.
25. Tanaka M, Shimbo T, Kikuchi Y, Matsuda M, Kaneda Y. Sterile alpha motif containing domain 9 (SAMD9) is involved in death signaling of malignant glioma treated with inactivated Sendai virus particle (HVJ-E) or type I interferon. Int J Cancer 2010;126:1982-91.
26. Kaneda Y, Nakajima T, Nishikawa T, Yamamoto S, Ikegami H, Suzuki N, et al. HVJ (hemagglutinating virus of Japan) envelope vector as a versatile gene delivery system. Mol Ther 2002;6:219-26. (Pubitemid 36336129)
27. Segawa H, Kato M, Yamashita T, Taira H. The roles of individual cysteine residues of Sendai virus fusion protein in intracellular transport. J Biochem 1998;123:1064-72. (Pubitemid 28305988)
28. Edamura K, Nasu Y, Takaishi M, Kobayashi T, Abarzua F, Sakaguchi M, et al. Adenovirus-mediated REIC/Dkk-3 gene transfer inhibits tumor growth and metastasis in an orthotopic prostate cancer model. Cancer Gene Ther 2007;14:765-72. (Pubitemid 47262756)
29. Hatano K, Miyamoto Y, Nonomura N, Kaneda Y. Expression of gangliosides, GD1a and sialyl paragloboside, is regulated by NF-κB-dependent transcriptional control of a2,3-sialyltransferase I, II and VI in human castration-resistant prostate cancer cells. Int J Cancer 2011;129:1838-47.
30. Yoneyama M, Kikuchi M, Matsumoto K, Imaizumi T, Miyagishi M, Taira K, et al. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J Immunol 2005;175:2851-8. (Pubitemid 41170502)
31. Yoneyama M, Fujita T. Recognition of viral nucleic acids in innate immunity. Rev Med Virol 2010;20:4-22.
32. Rehwinkel J, Tan CP, Goubau D, Schulz O, Pichlmair A, Bier K, et al. RIG-I detects viral genomic RNA during negative-strand RNA virus infection. Cell 2010;140:397-408.
33. Okada Y. Sendai virus-induced cell fusion. In:Duzgunes N, editor. Methods in enzymology. Vol. 221. San Diego, CA: Academic Press, Inc.; 1993. p. 18-41.
34. Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nature Rev Cancer 2008;8:782-97.
35. Gonzalvez F, Ashkenazi A. New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene 2010;29:4752-65.
36. Eitz Ferrer P, Potthoff S, Kirschnek S, Gasteiger G, Kastenmüller W, Ludwig H, et al. Induction of Noxa-mediated apoptosis by modified vaccinia virus Ankara depends on viral recognition by cytoplasmic helicases, leading to IRF-3/IFN-β-dependent induction of pro-apoptotic Noxa. PLoS Pathogens 2011;7:e1002083.
37. Romieu-Mourez R, Solis M, Nardin A, Goubau D, Baron-Bodo V, Lin R, et al. Distinct roles for IFN regulatory factor (IRF)-3 and IRF-7 in the activation of antitumor properties of human macrophages. Cancer Res 2006;166:10576-85. (Pubitemid 44799781)
38. Tang ED, Wang C-Y. TRAF5 is a downstream target of MAVS in antiviral innate immune signaling. PLoS ONE 2010;5:e9172.
39. Kato A, Ohnishi Y, Kohase M, Saito S, Tashiro M, Nagai Y. Y2, the smallest of the Sendai virus C proteins, is fully capable of both counteracting the antiviral action of interferons and inhibiting viral RNA synthesis. J Virol 2001;75:3802-10. (Pubitemid 32246389)
40. Sakai K, Kohri T, Tashiro M, Kishino Y, Kido H. Sendai virus infection changes the subcellular localization of tryptase Clara in rat bronchiolar epithelial cells. Eur Respir J 1994;7:686-92. (Pubitemid 24122963)
41. Lopez CB, Moltedo B, Alexopoulou L, Bonifaz L, Flavell RA, Moran TM. TLR-independent induction of dendritic cell maturation and adaptive immunity by negative-strand RNA viruses. J Immunol 2004;173:6883-9.
42. Kato H, Takahasi K, Fujita T. RIG-I-like receptors: cytoplasmic sensors for non-self RNA. Immunol Rev 2011;243:91-8
43. Barbalat R, Ewald SE, Mouchess ML, Barton GM. Nucleic acid recognition by the innate immune system. Annu Rev Immunol 2011;29:185-214.
44. Besch R, Poeck H, Hohenauer T, Senft D, Häcker G, Berking C, et al. Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J Clin Invest 2009;119:2399-411.
45. Ploner C, Koe fler R, Villunger A. Noxa: at the tip of the balance between life and death. Oncogene 2009;27:S84-92.
46. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007;26:1324-37. (Pubitemid 46328466)
47. Zullo JM, Demarco IA, Piqué-Regi R, Gaffney DJ, Epstein CB, Spooner CJ, et al. DNA sequence-dependent compartmentalization and silencing of chromatin at the nuclear lamina. Cell 2012;149:1474-87.
48. Baylin SB, Jones PA. A decade of exploring the cancer epigenomebiological and translational implications. Nat Rev Cancer 2011;11:726-34.
49. Kaneda Y, Yamamoto S, Nakajima T. Development of HVJ envelope vector and its application to gene therapy. In:Huang L, Hung M-C, Wagner E, editors. Non-viral vectors for gene therapy. San Diego: Elsevier Academic Press; 2005. p. 307-32. (Pubitemid 43580672)